Improving Outcomes in Anaplastic Lymphocyte Kinase-Positive Metastatic Non-Small Cell Lung Cancer
Anaplastic lymphocyte kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) with central nervous system metastasis is challenging to treat. Over the past decade, approval of ALK inhibitors has improved survival and provided patients with overall greater quality of life than that seen with chemotherapy. A practical approach to the treatment of ALK-positive NSCLC is presented in this article.
